menu
    • menu

    Company profile for Abcuro, Inc

    NEW Drugs in Dev: 2
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Abcuro’s mission is to develop a new class of immune modulatory bio-therapeutics for treating both autoimmunity and cancer. We leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Our intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartm...
    Abcuro’s mission is to develop a new class of immune modulatory bio-therapeutics for treating both autoimmunity and cancer. We leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Our intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Abcuro, IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    90 Bridge Street, Suite 100, Newton, MA 02458
    Telephone
    Telephone
    +1 617-714-9773
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://abcuro.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/abcuro-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof WW Bologna

    Cosmoprof WW Bologna

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof WW Bologna

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abcuro Unveils Ulviprubart Phase 2/3 MUSCLE Study Results
    Abcuro Unveils Ulviprubart Phase 2/3 MUSCLE Study Results

    26 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-26/abcuro-presents-results-from-phase-23-muscle-study-of-ulviprubart-in-patients-with-inclusion-body-m

    PHARMIWEB
    26 Mar 2026
    Share Share
    Abcuro's KLRG1 Antibody Flunks Phase 2/3 Muscle Disease Study
    Abcuro's KLRG1 Antibody Flunks Phase 2/3 Muscle Disease Study

    25 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/abcuros-klrg1-antibody-flunks-phase-23-muscle-disease-study

    FIERCE BIOTECH
    25 Feb 2026
    Share Share
    Abcuro Presents Phase 1 Ulviprubart Data for T-LGLL at 67th ASH
    Abcuro Presents Phase 1 Ulviprubart Data for T-LGLL at 67th ASH

    08 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251208779518/en/Abcuro-Presents-Interim-Phase-1-Data-Evaluating-Ulviprubart-in-Patients-with-T-Cell-Large-Granular-Lymphocytic-Leukemia-at-the-67th-American-Society-of-Hematology-Annual-Meeting

    BUSINESSWIRE
    08 Dec 2025
    Share Share
    Abcuro To Present Ulviprubart Phase 1 Data at ASH Annual Meeting
    Abcuro To Present Ulviprubart Phase 1 Data at ASH Annual Meeting

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251102053831/en/Abcuro-to-Present-Interim-Phase-1-Data-Evaluating-Ulviprubart-in-Patients-with-T-Cell-Large-Granular-Lymphocytic-Leukemia-at-the-67th-American-Society-of-Hematology-Annual-Meeting

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Abcuro Appoints George Eldridge as Chief Financial Officer
    Abcuro Appoints George Eldridge as Chief Financial Officer

    18 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250818738832/en/Abcuro-Appoints-George-Eldridge-as-Chief-Financial-Officer

    BUSINESSWIRE
    18 Aug 2025
    Share Share
    Resonant Clinical Solutions Names Christophe Berthoux CEO
    Resonant Clinical Solutions Names Christophe Berthoux CEO

    09 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250609505124/en/Resonant-Clinical-Solutions-Appoints-Christophe-Berthoux-as-Chief-Executive-Officer

    BUSINESSWIRE
    09 Jun 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search